Due to its constantly growing incidence, obesity is an increasingly serious social and
medical problem. Available data on the use of novel oral anticoagulants in morbidly obese …

Aims To investigate the relationship between body mass index (BMI) and outcomes in
patients with atrial fibrillation (AF). Methods and results In the ENGAGE AF-TIMI 48 trial …

Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …

Purpose Although direct oral anticoagulants are effective and safe in preventing stroke in
atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with …

Abstract Purpose of Review The purpose of this review is to examine the safety and
effectiveness of direct oral anticoagulants and provide recommendations for the treatment of …

Objectives Current evidence indicates that the pharmacokinetic profile of rivaroxaban is not
significantly impacted by body weight. However, real-world data are needed to better assess …

Evidence on the efficacy and safety of low-dose direct oral anticoagulant (DOAC) in older
patients with nonvalvular atrial fibrillation is still scarce. We conducted a single-center …

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …

Abstract Introduction Direct oral anticoagulants (DOACs) are widely employed for
antithrombotic prophylaxis in patients with atrial fibrillation (AF). However, there is still …

Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …